Time to Decision and Treatment with tPA (Tissue-Type Plasminogen Activator) Using Telemedicine Versus an Onboard Neurologist on a Mobile Stroke Unit
Stroke 49:1528-1530, Bowry, R.,et al, 2018
Magnetic Resonance Imaging Selection for Endovascular Stroke Therapy
Stroke 49:1402-1406, Simonsen, C.Z.,et al, 2018
Diagnosis and Management of Active Intracranial Atherosclerotic Disease
Stroke 49:e221-e223, Narwal, P.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Autoimmune Pancerebellitis Associated with Pembrolizumab Therapy
Neurol 91:91-93, Vitt, J.R.,et al, 2018
Clinicopathologic Conference, Vitamin C Deficiency (Scurvey), Vitamin B6 & Folate Deficiencies
NEJM 379:282-289, Case 22-2018, 2018
Drug Reaction with Eosinophilia and Systemic Symptoms after Daclizamub Therapy
Neurol 91:e359-e363, Rauer,S.,et al, 2018
Clinicopathological Conference, Insulinoma
NEJM 379:376-384, Case 23-2018, 2018
White Matter Lesion Related to Decompression Sickness Following Extreme Breath-Hold Diving
Neurol 91:847-848, Guerreiro, C.,et al, 2018
Use of Newer Disease-Modifying Therapies in Pediatric Multiple Sclerosis in the US
Neurol 91:e1778-e1787, Krysko, K.M.,et al, 2018
Preventive Migraine Drug Approved
JAMA 320:1746, , 2018
Hearing and Vision Loss in an Older Man
JAMA Neurol 75:1439-1440, Ho, V.M.,et al, 2018
Surviving Cerebral Malaria
Neurol 91:978-979, Wijdicks, E.F.M. & Park, J.G., 2018
Efficacy and Tolerability of Erenumab in Patients with Episodic Migraine in Whom Two-of-Four Previous Preventive Treatments were Unsuccessful: A Randomised, Double-Blind, Placebo-Controlled, Phase 3b Study
Lancet 392:2280-2287,2241, Reuter, U.,et al, 2018
Implications of the WAKE-UP Trial
Stroke 49:3115-3117, Silver, B. & Arnold, M., 2018
Pembrolizumab-Induced Myasthenia Gravis
Neurol 91:e1365-e1367, Algaeed, M.,et al, 2018
Selenium Toxicity Associated with Reversible Leukoencephalopathy and Cortical Blindness
JAMA Neurol 75:1282-1283, Rae, W.,et al, 2018
D-dimer >2.785 �g/ml and multiple infarcts =3 vascular territories are two characteristics of identifying cancer-associated ischemic stroke patients
Neurol Res 40:948-954, Wang, J.,et al, 2018
Spinal Cord Infarction Because of Spontaneous Vertebral Artery Dissection
Stroke 49:e314-e317, Montalvo, M.,et al, 2018
Acute demyelinating polyneuropathy induced by nivolumab
JNNP 89:435-437, Fukumoto, Y.,et al, 2018
Acute Viral Encephalitis
NEJM 379:357-366, Tyler,K.L., 2018
Use of Vitamins and Dietary Supplements by Patients with Multiple Sclerosis, A Review
JAMA Neurol 75:1013-1021, Evans,E.,et al, 2018
Intravenous tPA (Tissue-Type Plasminogen Activator) in Patients with Acute Ischemic Stroke Taking Non-Vitamin K Antagonist Oral Anticoagulants Preceding Stroke
Stroke 49:2237-2240, Jin, C.,et al, 2018
Immune Checkpoint Inhibitor-Related Myositis and Myocarditis in Patients with Cancer
Neurol 91:e985-e994, Touat, M.,et al, 2018
Interventions for Improving Modifiable Risk Factor Control in the Secondary Prevention of Stroke
Stroke 49:e301-e302, Bridgwood, B.,et al, 2018
Mechanical Thrombectomy Outcomes with or without Intravenous Thrombolysis
Stroke 49:2383-2390, Gariel, F.,et al, 2018
Endovascular Stroke Therapy in the Late Time Window
Stroke 49:2559-2561, Schellinger, P.D. & Demaerschalk, B.M., 2018
Myasthenia Gravis Following Alemtuzumab Therapy for Multiple Sclerosis
Neurol 91:622-624, Midaglia, L.,et al, 2018
Bilateral Basal Ganglia Necrosis Secondary to Methamphetamine
MDCP 5:55-556, Sanchez,A. et al, 2018
Central Nervous System Brucellosis Granuloma and White Matter Disease in Immunocompromised Patient
Emerg Infect Dis 23:978-981, Alqwaifly,M.,et al, 2017
Intracranial Meningeal Enhancement Characterization
Rev Colomb Radiol 28:4709-4716, Mera, J.L.C.,et al, 2017
Interim Results from the CATNON trial (EORTC study 260-53-22054) of treatment with Concurrent and Adjuvant Temozolomide for 1p/19q non-co-deleted anaplastic glioma: A phase 3, randomized, open-label intergroup study
Lancet 390:1645-1653, Van Den Bent, M.J.,et al, 2017
Elsberg Syndrome
Neurol Neuroimmunol Neuroinflamm 4:e355-e362, Savoldi, F.,et al, 2017
Disseminated Aspergillosis in an HIV-positive Cannabis user taking steroid treatment
Lancet Infect Dis 17:882, Salam, A.P. & Pozniak, A.L., 2017
Clinicopathologic Conference, Paroxysmal Nocturnal Hemoglobinuria
NEJM 377:2581-2590, Case 40-2017, 2017
Direct Mechanical Thrombectomy Versus Combined Intravenous and Mechanical Thrombectomy in Large-Artery Anterior Circulation Stroke
Stroke 48:2912-2918, Fischer, U.,et al, 2017
Cytotoxic Lesions of the Corpus Callosum That Show Restricted Diffusion: Mechanisms, Causes, and Manifestations
RadioGraphics 37:562-576, Starkey, J.,et al, 2017
The Contrast Enhancement of Intracranial Arterial Wall on High-Resolution MRI and Its Clinical Relevance in Patients with Moyamoya Vasculopathy
Sci Rep 7:44264 doi:10.1038/srep44264, Wang, M.,et al, 2017
The Expanding Prominence of Toxic Leukoencephalopathy
J Neuropsychiatry Clin Neurosci 29:308-318, Filley,C.M.,et al, 2017
Idiopathic Hyperammonemia after Solid Organ Transplantation: Primarily a Lung Problem? A Single-Center Experience and Systematic Review
ClinTransplant 31:e12957, Krutsinger, D.,et al, 2017
A Case of Statin-Associated Autoimmune Myopathy
Clin Med Insights: Case Reports 10:1-4, Sweidan, A.J.,et al, 2017
Alemtuzumab CARE-MS I 5-year follow-up
Neurol 89:1107-1116, Havrdova, E.,et al, 2017
Alemtuzumab CARE-MS II 5-year follow-up
Neurol 89:1117-1126, Coles, A.J.,et al, 2017
A 27-year-old man with unsteady gait
Neurol 89:e120-e123, Fernandez, D.,et al, 2017
Rituximab as Treatment for anti-MuSK myasthenia gravis
Neurol 89:1069-1077, Hehir, M.K.,et al, 2017
DAWN: Thrombectomy Effective Up to 24 Hours after Stroke
Medscape May, Hughes, S., 2017
Computed Tomographic Perfusion to Predict Response to Recanalization in Ischemic Stroke
Ann Neurol 81:849-856, Lansberg, M.G.,et al, 2017
Intravenous Immune Globulin: Adverse Effects
UptoDate June, Perez, E.E. & Silvergleid, A.J., 2017
Clinicopathologic Conference, Atypical Immunoblastic Reaction that was consistent with Primary Epstein-Barr virus Infecton
NEJM 377:677-688, Case 25-2017, 2017